[1] Bernal W, Wendon J. Acute liver failure. N Engl J Med, 2013, 369,26: 2525-2534.
[2] Bernal W, Jalan R, Quaglia A, et al. Acute-on-chronic liver failure. The Lancet, 2015, 386: 1576-1587.
[3] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014, 60: 2099-2108.
[4] 中华医学会感染病学会分会肝衰竭与人工肝学组, 中华医学会感染病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 中华临床感染病杂志, 2012, 5,321-327.
[5] Struecker B, Raschzok N, Sauer IM. Liver support strategies: cutting-edge technologies. Nat Rev Gastroenterol Hepatol, 2014, 11: 166-176.
[6] Shi XL, Gao Y, Yan Y, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes. Cell Res, 2016, 26: 206-216.
[7] Stevens KR, Scull MA, Ramanan V, et al. In situ expansion of engineered human liver tissue in a mouse model of chronic liver disease. Sci Transl Med, 2017, 9,399.
[8] Liu M, Yang J, Hu W, et al. Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure. Biomed Mater, 2016, 11: 015008.
[9] Demetriou AA, Brown RS, Jr. Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg, 2004, 239: 660-667.
[10] Glorioso JM, Mao SA, Rodysill B, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. J Hepatol, 2015, 63: 388-398.
[11] Di Nicuolo G, D'alessandro A, Andria B, et al. Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver. Xenotransplantation, 2010, 17: 431-439.
[12] Kinasiewicz A, Gautier A, Lewinska D, et al. Three-dimensional growth of human hepatoma C3A cells within alginate beads for fluidized bioartificial liver. Int J Artif Organs, 2008, 31: 340-347.
[13] Hoekstra R, Nibourg GA, Van Der Hoeven TV, et al. The HepaRG cell line is suitable for bioartificial liver application. Int J Biochem Cell Biol, 2011, 43: 1483-1489.
[14] Totsugawa T, Yong C, Rivas-Carrillo JD, et al. Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with Tamoxifen-mediated self-recombination. J Hepatol, 2007, 47: 74-82.
[15] Nagamoto Y, Tashiro K, Takayama K, et al. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. Biomaterials, 2012, 33: 4526-4534.
[16] Takahashi K, Tanabe K, Ohnuli M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131,5: 861-872.
[17] Pournasr B, Mohamadnejad M, Bagheri M, et al. In vitro differentiation of human bone marrow mesenchymal stem cells into hepatocyte-like cells. Arch Iran Med, 2011, 14,4: 244-249.
[18] Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation, 2002, 74,12: 1735-1746.
[19] Sussman NL, Kelly JH. Artificial liver. Clin Gastroenterol Hepatol, 2014, 12,9: 1439-1442.
[20] Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology, 1996, 24,6: 1446-1451.
[21] Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J, 2001, 47: 471-475.
[22] Nibourg GA, Hoekstra R, Van Der Hoeven TV, et al. Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver. Liver Int, 2013, 33: 516-524.
[23] Zhang SC, Liu T, Chen L, et al. Bifunctional polyethersulfone hollow fiber with a porous, single-layer skin for use as a bioartificial liver bioreactor. J Mater Sci Mater Med, 2012, 23: 2001-2011.
[24] Van DE Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs, 2002, 25: 950-959.
[25] Sauer IM, Kardrdassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support - phase I study with primary porcine liver cells. Xenotransplantation, 2003, 10: 460-469.
[26] Sauer IM, Zeilinger K, Pless G, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis--treatment of a patient with primary graft non-function. J Hepatol, 2003, 39: 649-653.
[27] Nicolas CT, Hickey RD, Chen HS, et al. Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. Stem Cells, 2017, 35: 42-50. |
